[go: up one dir, main page]

MA38957A1 - Combinaisons d'anti-inflammatoire non stéroïdien (ains) et de ligand des récepteurs sigma - Google Patents

Combinaisons d'anti-inflammatoire non stéroïdien (ains) et de ligand des récepteurs sigma

Info

Publication number
MA38957A1
MA38957A1 MA38957A MA38957A MA38957A1 MA 38957 A1 MA38957 A1 MA 38957A1 MA 38957 A MA38957 A MA 38957A MA 38957 A MA38957 A MA 38957A MA 38957 A1 MA38957 A1 MA 38957A1
Authority
MA
Morocco
Prior art keywords
inflammatory
nsaid
combinations
receptor ligand
nonsteroidal anti
Prior art date
Application number
MA38957A
Other languages
English (en)
Other versions
MA38957B1 (fr
Inventor
Daniel Zamanillo-Castanedo
Enrique Portillo-Salido
Enrique-José Cobos-Del-Moral
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA38957A1 publication Critical patent/MA38957A1/fr
Publication of MA38957B1 publication Critical patent/MA38957B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une combinaison synergique qui comporte un ligand sigma, en particulier un ligand sigma de la formule générale (i), et un composé d'anti-inflammatoire non stéroïdien (ains), un médicament comportant ladite combinaison de substances actives et l'utilisation de ladite combinaison de substances actives pour la fabrication d'un médicament, en particulier pour la prophylaxie et/ou le traitement de la douleur.
MA38957A 2013-09-12 2016-04-07 Combinaisons d'anti-inflammatoire non stéroïdien (ains) et de ligand des récepteurs sigma MA38957B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382353 2013-09-12
PCT/EP2014/069370 WO2015036470A1 (fr) 2013-09-12 2014-09-11 Combinaisons d'anti-inflammatoire non stéroïdien (ains) et de ligand des récepteurs sigma

Publications (2)

Publication Number Publication Date
MA38957A1 true MA38957A1 (fr) 2016-04-29
MA38957B1 MA38957B1 (fr) 2016-11-30

Family

ID=49223707

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38957A MA38957B1 (fr) 2013-09-12 2016-04-07 Combinaisons d'anti-inflammatoire non stéroïdien (ains) et de ligand des récepteurs sigma

Country Status (17)

Country Link
US (1) US20160220574A1 (fr)
EP (1) EP3043795A1 (fr)
JP (1) JP2016530322A (fr)
KR (1) KR20160054547A (fr)
CN (1) CN105611925A (fr)
AR (1) AR100021A1 (fr)
AU (1) AU2014320399A1 (fr)
CA (1) CA2922330A1 (fr)
IL (1) IL244200A0 (fr)
MA (1) MA38957B1 (fr)
MX (1) MX2016002892A (fr)
PH (1) PH12016500356A1 (fr)
RU (1) RU2016113713A (fr)
SG (1) SG11201601304XA (fr)
TN (1) TN2016000084A1 (fr)
TW (1) TW201605433A (fr)
WO (1) WO2015036470A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (fr) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2353598A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire
EP2353591A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance
EP2388005A1 (fr) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention et/ou le traitement du vomissement induit par la chimiothérapie ou la radiothérapie
EP2415471A1 (fr) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans l'hyperalgie induite par opioïdes
EP2524694A1 (fr) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans la douleur liée au diabète de type 2
CN105873578A (zh) 2013-12-17 2016-08-17 埃斯蒂维实验室股份有限公司 血清素－去甲肾上腺素再摄取抑制剂(SNRIs)和σ受体配体组合物
CN107459510B (zh) * 2016-06-06 2021-06-25 华东师范大学 异恶唑类化合物及其应用
EP3415143A1 (fr) 2017-06-16 2018-12-19 Kai-Uwe Kern Bromhexine destiné au traitement de la douleur
CA3121202A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composes pyrrole et pyrazole et leurs procedes d'utilisation
WO2021002982A1 (fr) * 2019-07-03 2021-01-07 Exxonmobil Research And Engineering Company Matériaux à structures métallo-organiques comprenant un ligand de pyrazolylbenzoate et leurs procédés de production
EP4233854A3 (fr) * 2019-11-01 2024-01-17 Piedmont Animal Health Inc. Formulations thérapeutiques et leurs utilisations
WO2024105225A1 (fr) * 2022-11-18 2024-05-23 Universitat De Barcelona Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur
CN120860019A (zh) * 2024-04-30 2025-10-31 厦门大学 氯苯唑酸在激活rxr活性中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068838B1 (fr) * 1981-06-26 1986-09-17 The Upjohn Company Procédé analgésique et composition
AU2062892A (en) * 1991-08-16 1993-02-18 Mcneil-Ppc, Inc. Potentiation of antitussive effect of dextromethorphan
EP1781618B1 (fr) * 2004-08-27 2012-10-03 Laboratorios Del Dr. Esteve, S.A. Inhibiteurs de recepteur sigma
EP1634872A1 (fr) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Dérivés de pyrazole en tant qu'inhibiteurs des récepteurs sigma
EP2116539A1 (fr) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2292236A1 (fr) * 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention ou le traitement de douleurs induites par la chimiothérapie
EP2353598A1 (fr) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire
EP2460519A1 (fr) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma pour la douleur du cancer des os
EP2524694A1 (fr) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans la douleur liée au diabète de type 2
JP6169716B2 (ja) * 2012-11-05 2017-07-26 ザフゲン，インコーポレイテッド 肝疾患を治療する方法

Also Published As

Publication number Publication date
CN105611925A (zh) 2016-05-25
US20160220574A1 (en) 2016-08-04
WO2015036470A1 (fr) 2015-03-19
JP2016530322A (ja) 2016-09-29
MX2016002892A (es) 2016-06-10
RU2016113713A (ru) 2017-10-17
TN2016000084A1 (en) 2017-07-05
MA38957B1 (fr) 2016-11-30
IL244200A0 (en) 2016-04-21
PH12016500356A1 (en) 2016-05-16
AU2014320399A1 (en) 2016-03-10
CA2922330A1 (fr) 2015-03-19
SG11201601304XA (en) 2016-03-30
RU2016113713A3 (fr) 2018-06-29
AR100021A1 (es) 2016-09-07
KR20160054547A (ko) 2016-05-16
TW201605433A (zh) 2016-02-16
EP3043795A1 (fr) 2016-07-20

Similar Documents

Publication Publication Date Title
MA38957B1 (fr) Combinaisons d'anti-inflammatoire non stéroïdien (ains) et de ligand des récepteurs sigma
MA39146A1 (fr) Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
CR20160170A (es) Moduladores del factor del complemento b
EA201791299A1 (ru) Микроинкапсулированные композиции каннабиноидов
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA39147B1 (fr) Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
MX2016001446A (es) Inhibidores de heterobicicloaril rorc2 y metodos de uso de los mismos.
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
PE20151526A1 (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod
MX374340B (es) Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.
BR112015023463A2 (pt) uso de sedoeptulose para prevenção ou tratamento de inflamação
PE20170305A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
EA201990162A1 (ru) Фармацевтические композиции
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
BR112017008835A2 (pt) composto, e, composição farmacêutica.
BR112015030093A2 (pt) preparação oral para redução da erosão dentinária, composição oral e uso da preparação
EA201401142A1 (ru) Замещенные 6-аминоникотинамиды, несущие он-содержащую группу, в качестве модуляторов kcnq2/3
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении
FR3075602B1 (fr) Produit de combinaison pour la prevention et le traitement des insuffisances veineuses chroniques
CR20190329A (es) MODULADORES DEL FACTOR DEL COMPLEMENTO B (Divisional 2016-0170)
FR3048359B1 (fr) Utilisation d’au moins un filtre uva long pour prevenir l’apparition de sensations dysesthesiques
CU20160018A7 (es) Composiciones farmacéuticas de compuestos que inhiben la actividadde tirosina cinasa y sus métodos de preparación